Relevant bibliographies by topics / Adenoviru

Academic literature on the topic 'Adenoviru'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Adenoviru.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Adenoviru"

1

O'Prey, Jim, Simon Wilkinson, and Kevin M. Ryan. "Tumor Antigen LRRC15 Impedes Adenoviral Infection: Implications for Virus-Based Cancer Therapy." Journal of Virology 82, no. 12 (April 2, 2008): 5933–39. http://dx.doi.org/10.1128/jvi.02273-07.

Full text
Abstract:
ABSTRACT Adenoviruses for gene or oncolytic therapy are under development. Notable among these strategies is adenoviral delivery of the tumor suppressor p53. Since all therapeutics have limitations in certain settings, we have undertaken retroviral suppressor screens to identify genes conferring resistance to adenovirus-delivered p53. These studies identified the tumor antigen LRRC15, which is frequently overexpressed in multiple tumor types, as a repressor of cell death due to adenoviral p53. LRRC15, however, does not impede p53 function per se but impedes adenoviral infection. Specifically, LRRC15 causes redistribution of the coxsackievirus-adenovirus receptor away from the cell surface. This effect is manifested in less adenoviral binding to the surfaces of LRRC15-expressing cells. This discovery, therefore, not only is important for understanding adenoviral biology but also has potentially important implications for adenovirus-based anticancer therapeutics.
APA, Harvard, Vancouver, ISO, and other styles
2

Zhu, Jiangao, Xiaopei Huang, and Yiping Yang. "Innate Immune Response to Adenoviral Vectors Is Mediated by both Toll-Like Receptor-Dependent and -Independent Pathways." Journal of Virology 81, no. 7 (January 17, 2007): 3170–80. http://dx.doi.org/10.1128/jvi.02192-06.

Full text
Abstract:
ABSTRACT Recombinant adenoviral vectors have been widely used for gene therapy applications and as vaccine vehicles for treating infectious diseases such as human immunodeficiency virus disease. The innate immune response to adenoviruses represents the most significant hurdle in clinical application of adenoviral vectors for gene therapy, but it is an attractive feature for vaccine development. How adenovirus activates innate immunity remains largely unknown. Here we showed that adenovirus elicited innate immune response through the induction of high levels of type I interferons (IFNs) by both plasmacytoid dendritic cells (pDCs) and non-pDCs such as conventional DCs and macrophages. The innate immune recognition of adenovirus by pDCs was mediated by Toll-like receptor 9 (TLR9) and was dependent on MyD88, whereas that by non-pDCs was TLR independent through cytosolic sensing of adenoviral DNA. Furthermore, type I IFNs were pivotal in innate and adaptive immune responses to adenovirus in vivo, and type I IFN blockade diminished immune responses, resulting in more stable transgene expression and reduction of inflammation. These findings indicate that adenovirus activates innate immunity by its DNA through TLR-dependent and -independent pathways in a cell type-specific fashion, and they highlight a critical role for type I IFNs in innate and adaptive immune responses to adenoviral vectors. Our results that suggest strategies to interfere with type I IFN pathway may improve the outcome of adenovirus-mediated gene therapy, whereas approaches to activate the type I IFN pathway may enhance vaccine potency.
APA, Harvard, Vancouver, ISO, and other styles
3

Nestić, Davor, Ksenija Božinović, Isabela Pehar, Rebecca Wallace, Alan L. Parker, and Dragomira Majhen. "The Revolving Door of Adenovirus Cell Entry: Not All Pathways Are Equal." Pharmaceutics 13, no. 10 (September 29, 2021): 1585. http://dx.doi.org/10.3390/pharmaceutics13101585.

Full text
Abstract:
Adenoviruses represent exceptional candidates for wide-ranging therapeutic applications, from vectors for gene therapy to oncolytics for cancer treatments. The first ever commercial gene therapy medicine was based on a recombinant adenovirus vector, while most recently, adenoviral vectors have proven critical as vaccine platforms in effectively controlling the global coronavirus pandemic. Here, we discuss factors involved in adenovirus cell binding, entry, and trafficking; how they influence efficiency of adenovirus-based vectors; and how they can be manipulated to enhance efficacy of genetically modified adenoviral variants. We focus particularly on endocytosis and how different adenovirus serotypes employ different endocytic pathways to gain cell entry, and thus, have different intracellular trafficking pathways that subsequently trigger different host antiviral responses. In the context of gene therapy, the final goal of the adenovirus vector is to efficiently deliver therapeutic transgenes into the target cell nucleus, thus allowing its functional expression. Aberrant or inefficient endocytosis can impede this goal, therefore, it should be considered when designing and constructing adenovirus-based vectors.
APA, Harvard, Vancouver, ISO, and other styles
4

Harrod, Kevin S., Bruce C. Trapnell, Kazuhisa Otake, Thomas R. Korfhagen, and Jeffrey A. Whitsett. "SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection." American Journal of Physiology-Lung Cellular and Molecular Physiology 277, no. 3 (September 1, 1999): L580—L588. http://dx.doi.org/10.1152/ajplung.1999.277.3.l580.

Full text
Abstract:
Surfactant protein A (SP-A) is a member of the collectin family of host defense molecules expressed primarily in the epithelial cells of the lung. To determine the role of SP-A in pulmonary adenoviral infection, SP-A-deficient (SP-A −/−) mice were intratracheally infected with a replication-deficient recombinant adenovirus, Av1Luc1. Lung inflammation was markedly increased in SP-A −/− compared with SP-A +/+ mice and was associated with increased hemorrhage and epithelial cell injury. Polymorphonuclear cells in bronchoalveolar lavage fluid (BALF) were increased in SP-A −/− mice after administration of adenovirus. Coadministration of adenovirus and purified human SP-A ameliorated adenoviral-induced lung inflammation in SP-A −/− mice. Concentrations of tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-1β were increased in BALF of SP-A −/− mice. Likewise, TNF-α, IL-6, macrophage inflammatory protein (MIP)-1α, monocyte chemotactic protein-1, and MIP-2 mRNAs were increased in lung homogenates from SP-A −/− mice 6 and 24 h after viral administration. Clearance of adenoviral DNA from the lung and uptake of fluorescent-labeled adenovirus by alveolar macrophages were decreased in SP-A −/− mice. SP-A enhances viral clearance and inhibits lung inflammation during pulmonary adenoviral infection, providing support for the importance of SP-A in antiviral host defense.
APA, Harvard, Vancouver, ISO, and other styles
5

Jogler, Christian, Dennis Hoffmann, Dirk Theegarten, Thomas Grunwald, Klaus Überla, and Oliver Wildner. "Replication Properties of Human Adenovirus In Vivo and in Cultures of Primary Cells from Different Animal Species." Journal of Virology 80, no. 7 (April 1, 2006): 3549–58. http://dx.doi.org/10.1128/jvi.80.7.3549-3558.2006.

Full text
Abstract:
ABSTRACT Oncolytic adenoviruses have emerged as a promising approach for the treatment of tumors resistant to other treatment modalities. However, preclinical safety studies are hampered by the lack of a permissive nonhuman host. Screening of a panel of primary cell cultures from seven different animal species revealed that porcine cells support productive replication of human adenovirus type 5 (Ad5) nearly as efficiently as human A549 cells, while release of infectious virus by cells from other animal species tested was diminished by several orders of magnitude. Restriction of productive Ad5 replication in rodent and rabbit cells seems to act primarily at a postentry step. Replication efficiency of adenoviral vectors harboring different E1 deletions or mutations in porcine cells was similar to that in A549 cells. Side-by-side comparison of the viral load kinetics in blood of swine and mice injected with Ad5 or a replication-deficient adenoviral vector failed to provide clear evidence for virus replication in mice. In contrast, evidence suggests that adenovirus replication occurs in swine, since adenoviral late gene expression produced a 13.5-fold increase in viral load in an individual swine from day 3 to day 7 and 100-fold increase in viral DNA levels in the Ad5-infected swine compared to the animal receiving a replication-deficient adenovirus. Lung histology of Ad5-infected swine revealed a severe interstitial pneumonia. Although the results in swine are based on a small number of animals and need to be confirmed, our data strongly suggest that infection of swine with human adenovirus or oncolytic adenoviral vectors is a more appropriate animal model to study adenoviral pathogenicity or pharmacodynamic and toxicity profiles of adenoviral vectors than infection of mice.
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Minhyeok, Seulgi Kim, Oh Jung Kwon, Ji Hye Kim, Inbeom Jeong, Ji Woong Son, Moon Jun Na, Yoo Sang Yoon, Hyun Woong Park, and Sun Jung Kwon. "Treatment of Adenoviral Acute Respiratory Distress Syndrome Using Cidofovir With Extracorporeal Membrane Oxygenation." Journal of Intensive Care Medicine 32, no. 3 (November 30, 2016): 231–38. http://dx.doi.org/10.1177/0885066616681272.

Full text
Abstract:
Adenovirus infections are associated with respiratory (especially upper respiratory) infection and gastrointestinal disease and occur primarily in infants and children. Although rare in adults, severe lower respiratory adenovirus infections including pneumonia are reported in specific populations, such as military recruits and immunocompromised patients. Antiviral treatment is challenging due to limited clinical experience and lack of well-controlled randomized trials. Several previously reported cases of adenoviral pneumonia showed promising efficacy of cidofovir. However, few reports discussed the efficacy of cidofovir in acute respiratory distress syndrome (ARDS). We experienced 3 cases of adenoviral pneumonia associated with ARDS and treated with cidofovir and respiratory support, including extracorporeal membrane oxygenation (ECMO). All 3 patients showed a positive clinical response to cidofovir and survival at 28 days. Cidofovir with early ECMO therapy may be a therapeutic option in adenoviral ARDS. A literature review identified 15 cases of adenovirus pneumonia associated with ARDS.
APA, Harvard, Vancouver, ISO, and other styles
7

Reid, Tony, Andrew Kummel, Scott Caroen, Jaimin Shah, Bryan Oronsky, and Christopher Larson. "Abstract P3-07-20: Treatment of 4T1 Breast Cancer with Liposome-Encapsulated AdAPT-001, a TGF-beta Trap Encoded Oncolytic Adenovirus Currently in a Phase 1/2 Anticancer Trial." Cancer Research 83, no. 5_Supplement (March 1, 2023): P3–07–20—P3–07–20. http://dx.doi.org/10.1158/1538-7445.sabcs22-p3-07-20.

Full text
Abstract:
Abstract Adenoviral vectors have been used extensively for gene therapy. However, efficient infection of cells requires expression of the coxsackie-adenoviral receptor (CAR). Many tumor cells lack adequate expression of CAR and, hence, are not good targets for adenoviral based vectors. We have developed a unique nanoparticle (Epi-039) that can be used to efficiently introduce adenoviral vectors into tumor cells that have low or no CAR expression. We used the CAR-negative 4T1 mammary carcinoma model system, which represents a typical triple-negative breast cancer cell line (ER−, PR−, HER2−) and which is refractory to adenoviral infection to demonstrate effective transduction of an encapsulated oncolytic adenovirus. The adenovirus that was used is called AdAPT-001. This armed oncolytic virus, which is currently in a phase I/II clinical trial called BETA PRIME for the treatment of refractory cancers, expresses a TGFb receptor trap to neutralize the immunosuppressive cytokine, TGF beta. Overexpression of TGF-beta positively correlates with metastasis in breast carcinoma and thus confers a poorer prognosis. In this study, the unique Epi-039 nanoparticle carrying AdAPT-001 not only significantly enhanced the transduction efficiency of AdAPT-001 but also protected it from neutralization by natural antibodies in human whole blood. Accordingly, we demonstrate a significant increase (P value= 0.0029) in the expression of green fluorescent protein (GFP) in CAR-negative 4T1 cells infected with the encapsulated AdAPT-001 adenovirus but not the unencapsulated AdAPT-001 adenovirus. Additional in vivo studies using nanoparticle encapsulated adenoviral vectors including AdAPT-001 to treat breast cancer are underway for rapid translation to the clinic. Citation Format: Tony Reid, Andrew Kummel, Scott Caroen, Jaimin Shah, Bryan Oronsky, Christopher Larson. Treatment of 4T1 Breast Cancer with Liposome-Encapsulated AdAPT-001, a TGF-beta Trap Encoded Oncolytic Adenovirus Currently in a Phase 1/2 Anticancer Trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-07-20.
APA, Harvard, Vancouver, ISO, and other styles
8

Bründler, Marie-Anne, Norberto Rodriguez-Baez, Ron Jaffe, Arthur G. Weinberg, and Beverly Barton Rogers. "Adenovirus Ascending Cholangiohepatitis." Pediatric and Developmental Pathology 6, no. 2 (March 2003): 156–59. http://dx.doi.org/10.1007/s10024-002-0063-4.

Full text
Abstract:
Three children, two with liver transplants and one with acquired human immunodeficiency virus (HIV) infection, presented with hepatitis accompanied by elevated gamma glutamyl transpeptidase. Biopsies revealed cholangiohepatitis caused by adenovirus infection. There was a progressive loss of interlobular bile ducts in two of the patients. In one patient, infection of the biliary tree was marked by a necrotizing cholangitis, with adenoviral inclusions noted in the biliary epithelium. In each patient, there was evidence of adenovirus gastrointestinal infection. This is the first report of adenoviral infection of the biliary tree in humans. It is hypothesized that adenovirus cholangiohepatitis occurs as a result of ascending infection from the gastrointestinal tract to the biliary tree.
APA, Harvard, Vancouver, ISO, and other styles
9

Leen, Ann M., Anne Christin, Gary D. Myers, Hao Liu, Conrad R. Cruz, Patrick J. Hanley, Alana A. Kennedy-Nasser, et al. "Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation." Blood 114, no. 19 (November 5, 2009): 4283–92. http://dx.doi.org/10.1182/blood-2009-07-232454.

Full text
Abstract:
Abstract Viral infection or reactivation remains a major cause of morbidity and mortality after allogeneic stem cell transplantation. We now show that infusions of single cytotoxic T lymphocyte (CTL) lines (5 × 106-1.35 × 108 cells/m2) with specificity for 2 commonly detected viruses, Epstein-Barr virus (EBV) and adenovirus, can be safely administered to pediatric transplantation recipients receiving partially human leukocyte antigen–matched and haploidentical stem cell grafts (n = 13), without inducing graft-versus-host disease. The EBV-specific component of the CTLs expanded in vivo and persisted for more than 12 weeks, but the adenovirus-specific component only expanded in vivo in the presence of concomitant adenoviral infection. Nevertheless, adenovirus-specific T cells could be detected for at least 8 weeks in peripheral blood, even in CTL recipients without viral infection, provided the adenovirus-specific component of their circulating lymphocytes was first expanded by exposure to adenoviral antigens ex vivo. After infusion, none of these 13 high-risk recipients developed EBV-associated lymphoproliferative disease, while 2 of the subjects had resolution of their adenoviral disease. Hence, bispecific CTLs containing both EBV- and adenovirus-specific T cells can safely reconstitute an antigen responsive “memory” population of CTLs after human leukocyte antigen–mismatched stem cell transplantation and may provide antiviral activity. This trial was registered at www.clinicaltrials.gov as #NCT00590083.
APA, Harvard, Vancouver, ISO, and other styles
10

Debey, B. M., H. D. Lehmkuhl, C. Chard-Bergstrom, and L. A. Hobbs. "Ovine Adenovirus Serotype 7-associated Mortality in Lambs in the United States." Veterinary Pathology 38, no. 6 (November 2001): 644–48. http://dx.doi.org/10.1354/vp.38-6-644.

Full text
Abstract:
Adenoviral infections were diagnosed in three neonatal lambs that died spontaneously, and no other etiologic agents were identified. Clinical signs were anorexia, weakness, abdominal distention, and sudden death. Microscopic lesions consisted of multifocal necrotizing hepatitis, multifocal subacute interstitial nephritis, and loss of enterocytes from intestinal villi. Adenovirus inclusions were identified by light microscopy in the kidneys only. Adenoviral antigen, however, was identified in the liver, kidney, and intestine of the lambs by immunohistochemical techniques. An ovine adenovirus serotype 7, not previously isolated from sheep in the United States, was characterized from these lambs.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Adenoviru"

1

Silva, Luciana Helena Antoniassi da 1977. "Desenvolvimento de adenovírus recombinantes expres-sando as glicoproteínas F e G do metapneumovírus aviário (aMPV) e do vírus respiratório sincicial bo-vino(bRSV)." [s.n.], 2013. http://repositorio.unicamp.br/jspui/handle/REPOSIP/316630.

Full text
Abstract:
Orientadores: Clarice Weis Arns, Fernando Rosado Spilki
Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia
Made available in DSpace on 2018-08-22T19:38:08Z (GMT). No. of bitstreams: 1 Silva_LucianaHelenaAntoniassida_D.pdf: 3352165 bytes, checksum: 1c8836441214fc41a7890899268f1163 (MD5) Previous issue date: 2013
Resumo: Os membros da família Paramyxoviridae são vírus que causam infecções em humanos e animais de importância econômica global. Entre os membros desta família incluem patógenos de importância mundial para os humanos, como o vírus respiratório sincicial humano (hRSV), o metapneumovírus humano (hMPV) e vírus de importância em Medicina Veterinária, como o vírus respiratório sincicial bovino (bRSV) e o metapnemovírus aviário (aMPV). Os membros da família Paramyxoviridae, subfamília Pneumovirinae são vírus envelopados, não-segmentados dotados de genoma de RNA de fita simples com sentido negativo. Na primeira parte do estudo, desenvolvemos um adenovírus recombinante expressando a proteína F do aMPV. A expressão da proteína F foi determinada por Western Blot. Os níveis de transcrição do gene F foram avaliados por RT-PCR em tempo real, em células HEK-293 e células HEP-2. Foi realizada a imunização experimental de Ad-aMPV-F e foi analisada a indução de resposta de anticorpos em camundongos BALB/c. Os títulos de anticorpos neutralizantes foram detectados após a imunização com Ad-aMPV-F. Na segunda parte do trabalho o objetivo foi à construção de adenovírus recombinantes expressando a proteína F do bRSV. A proteína F parece ser um antígeno ideal para fins de diagnóstico. Utilizando anticorpo anti-V-5, uma banda de ~90 kDa foi detectada no sobrenadante de cultura de células HEK-293 infectadas com Ad-bRSV-F. Na terceira parte do estudo, o objetivo foi à construção de dois vetores adenovirais expressando as proteínas G do aMPV e bRSV, a expressão destas proteínas em células HEK-293 infectadas foi analisada pela expressão do gene repórter, da proteína verde fluorescente (GFP)
Abstract: The members of the family Paramyxoviridae are viruses that cause infectious in human and animals of importance to global economics. Among the member of this family include pathogens of importance global for humans such as human respiratory syncytial virus (hRSV), the human and metapneumovirus (hMPV) and of viruses importance in veterinary medicine, such as bovine respiratory syncytial virus (bRSV) and avian metapnemovírus (aMPV). The members of the Paramyxoviridae are enveloped, non-segmented viruses, with negative-sense single stranded genomes. In the first part of the study, we developed a recombinant adenovirus expressing the F protein of AMPV. The expression of F gene was determined by Western Blot. The levels of transcription were evaluated by RT-PCR in real time in HEK-293 cells and HEP-2 cells. Immunization experiment was carried out Ad-AMPV-F was analyzed and the induction of antibody response in BALB/c mice. The neutralizing antibody titers detected after immunization with Ad-AMPV-F. In the second part, the objective was to construct recombinant adenoviruses expressing the F protein of bRSV. Protein F appears to be an ideal antigen for diagnostic purposes. Using the anti-antibody AdV-5, a single band of ~ 90 kDa was detected in the culture supernatant in 293 cells infected with Ad-bRSV-F. In the third part of the study, the objective was to build two adenoviral vectors expressing the G protein of aMPV and bRSV and the expression of these proteins in infected HEK-293 cells were analyzed for expression of the reporter gene, green fluorescent protein (GFP)
Doutorado
Microbiologia
Doutora em Genética e Biologia Molecular
APA, Harvard, Vancouver, ISO, and other styles
2

TRIPODI, LORELLA. "INTESTINAL MICROBIOTA IS A MAJOR DETERMINANT IN THE RESPONSE TO ONCOLYTIC VACCINE IN A MOUSE MODEL OF MELANOMA." Doctoral thesis, Università degli Studi di Milano, 2021. http://hdl.handle.net/2434/884815.

Full text
Abstract:
Cancer immunotherapy has achieved tremendous results, however the outcome of therapies targeting immune inhibitory pathways, specifically CTLA-4 and the axis between programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) has many genetic and environmental sources of variability. Many studies demonstrated the influence of gut microbiome on immune checkpoint inhibitors (ICIs) outcome. Besides ICIs, oncolytic vaccines (OVs) are a promising therapeutic alternative in cancer immunotherapy with possible relevant contribution to treatment of several types of tumors; OVs are, in fact, able to convert immunologically “cold” tumors into “hot” ones. OVs represent an optimum candidate to combine with ICIs, increasing their response blockade both in immunogenic and poorly immunogenic tumors. We hypothesized that manipulation of intestinal gut microbiota could also affect OVs therapeutic efficacy; at this aim, we determined whether efficacy of the oncolytic adenovirus Ad5D24-CpG (Ad-CpG) therapy could be affected by the gut microbiome in a syngeneic mouse model of melanoma. Sterilization of the gut microbiota with highdose vancomycin impaired efficacy of Ad-CpG therapy, reducing the tumor-infiltrating IFN-gamma CD8 T-cell. Cohousing mice pre-treated with vancomycin and a control group, with consequent microbiota restoration, prior to treatment with Ad-CpG, ablated the negative effect of antibiotic, confirming that Ad-CpG-reduced efficacy was mediated by the intestinal microbiota. Considering the ability of Bifidobacterium as a positive regulator of antitumor immunity in vivo, by promoting pro-inflammatory signals in innate immune cells, we evaluated tumor regression in syngeneic mouse model of melanoma treated with a combination of Ad-CpG and Bifidobacterium spp. cocktail. The group receiving the combined regimen showed the best tumor control and an enrichment of bacteria belong to Firmicutes phylum, evaluated by fecal microbiome profiling by 16S rRNA. Our data indicates that gut microbiota affects the immune responses elicited by oncolytic adenovirus Ad-CpG and Bifidobacterium supplementations maximize its activity.
APA, Harvard, Vancouver, ISO, and other styles
3

Rauma-Pinola, T. (Tanja). "Adenovirus endocytosis and adenoviral gene transfer in cardiovascular and dermatologic disease models." Doctoral thesis, University of Oulu, 2004. http://urn.fi/urn:isbn:9514274342.

Full text
Abstract:
Abstract Adenoviral gene transfer is a valuable tool in molecular biology research. In order to be an efficient and safe vector, adenovirus structure and infection mechanism as well as molecular biology of the used transgene need to be well studied. The aim of this study was to evaluate the role of adenovirus as a gene transfer vector from several perspectives. Adenovirus uses receptor-mediated endocytosis in order to enter the target cell. The effect of Rab5 GTPase on adenovirus entry and gene transfer efficiency was examined first. Next, adenovirus was used as an investigatory tool in the cardiovascular research, focused on clarifying the role of adrenomedullin (AM) in heart and vascular remodeling. Finally, a model of adenoviral gene transfer into skin fibroblasts was used. The role of Rab5 GTPase in the adenovirus endocytosis was examined in HeLa cells using Cy3-labeled adenovirus, and gene transfer efficiency using β-galactosidase encoding adenovirus. Rab5 increased both adenovirus uptake and gene transfer, whereas dominant negative Rab5S34N decreased both endocytosis and gene transfer. The data indicate that Rab5 is needed in mediating the adenovirus uptake into the target cell. In the rat heart, adenovirus-mediated AM gene transfer transiently improved systolic function both in vivo and in vitro. AM caused activation of translocation of protein kinases C ε and δ, whereas phosphorylation of p38 mitogen activated protein kinase was decreased in the left ventricle. AM significantly attenuated the development of angiotensin II-induced cardiac hypertrophy. In rats with myocardial infarction, AM enhanced dilatation of left ventricle and thinning of anterior wall. The role of AM in neointima formation was evaluated in rat artery after endothelial injury. Intravascular AM gene transfer decreased neointimal growth and increased neointimal myofibroblasts apoptosis. These results show that AM regulates left ventricular systolic function and remodeling in the heart, and plays a role in pathological vascular remodeling. Adenovirus-mediated lysyl hydroxylase (LH) gene transfer into skin fibroblasts of type VI Ehlers-Danlos syndrome patient and rat skin increased functional LH production, elevated LH activity, and human LH mRNA production both in vitro and in vivo. LH gene replacement therapy may thus lead to possibilities to improve skin wound healing in Ehlers-Danlos syndrome patients.
APA, Harvard, Vancouver, ISO, and other styles
4

Rauschhuber, Christina. "Analysis of Adenovirus-Host Interactions to Improve Recombinant Adenoviral Vectors for Gene Therapy." Diss., lmu, 2011. http://nbn-resolving.de/urn:nbn:de:bvb:19-128560.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wiles, Karen Anna, and n/a. "Coxsackie and Adenovirus Receptor (CAR) expression is a potential limiting factor in adenoviral oncotheraphy." University of Otago. Dunedin School of Medicine, 2007. http://adt.otago.ac.nz./public/adt-NZDU20070619.161353.

Full text
Abstract:
Novel approaches to cancer treatment in the context of Gene Therapy have been gaining popularity as an alternative to conventional therapies which have proven to lack specificity, resulting in tumour cell resistance, tumour progression and mortality. As a consequence the use of adenoviruses has been widely developed not only as a replication deficient vector for gene therapy but also as a replication competent oncolytic agent designed to selectively target and kill tumour cells. Unfortunately their success in clinical application has been limited, and it has been suggested that a lack of the primary viral attachment receptor 'CAR' could be a barrier to infection by limiting access to target cells. If Ad/CAR binding is the rate limiting step for successful Ad therapy, it is essential to establish a CAR expression profile in normal and tumour tissue, and in tumour progression, to enable more effective targeted therapy. Furthermore, in the context of using adenovirus as an anticancer strategy by exploiting its replicative lysis, it is important to explore whether Ad success is affected by CAR expression and to identify factors downstream of CAR that may be influential in this process. In the first experimental chapter, an in vivo immunohistochemical analysis of tissue array slides determined CAR expression in a range of normal and tumour tissue. CAR was differentially expressed dependent on cell of origin, with normal stem cells and basal cells displaying very high CAR, signifying its importance in early development and differentiation. Epithelial cells were also high in CAR but its expression was negligible in mesenchymal, lymphoid and neural cells. This trend was also reflected in most tumour tissue albeit with a general decrease in CAR compared to corresponding normal tissue of the same organ. An exception was the blastic tumours which displayed high CAR reflecting their embryonic state of derivation. CAR expression also decreased in high grade, poorly differentiated tumours of the prostate, stomach and breast compared to their well differentiated counterparts. In the second experimental chapter, a more comprehensive study of breast cancer biopsy specimens was undertaken, to determine both the expression of CAR and the tumour suppressor gene p53 in relation to tumour grade. The rationale being that both loss of CAR expression and p53 mutation (resulting in loss of function), have been associated with tumour progression. It is possible that CAR and p53 interact directly or indirectly and may be modulated by each other. This study revealed a decrease in both CAR and hormone receptor expression and an increase in p53 'mutational' status with increasing tumour grade. These three factors when compared independently to tumour grade are statistically significant associations, implying that CAR expression and hormone responsiveness decrease with tumour progression and p53 function is compromised or lost via mutation. There was also a significant association between CAR expression and hormone receptor status, however a significant association between CAR expression and p53 status within the tumour grades was not found. Treatment outcome with Ads will also depend on defining factors downstream of CAR attachment that affect adenovirus 'permissivity', which is ultimately measured by viral replication and cell death, relying on the bystander effect to eradicate all tumour cells. The in vitro analysis revealed statistically significant associations between CAR receptor expression, 'infectivity' (virus infection) and permissivity. Cell lines that were more susceptible to Ad5 were generally of epithelial origin, had high CAR, and were easily infected. However there were exceptions and CAR was not the sole determinant in adenovirus cell entry nor in its ability to replicate and kill the cell. Permissivity was also related to p53 status. Thus, although CAR expression may indeed be a limiting factor, it is apparent that a combination of other events contributes to a deficient infection, especially in the deregulated tumour environment. The results presented in this thesis clearly demonstrate that there is more to the story of 'CAR' which hints that its role in viro-oncotherapy is not limited solely to its function as an attachment receptor for adenovirus but may also involve its function as a cell adhesion molecule and signal transducer. The further elucidation of these aspects of CAR�s potential role in the scheme of tumour biology may alter the course and strategy of cancer therapy in the future.
APA, Harvard, Vancouver, ISO, and other styles
6

Alkahlout, Amal S. "Establishment of Isoform-specific Coxsackievirus and Adenovirus Receptor Knockout Epithelial Cell Lines to Understand the Mechanism of Adenoviral Infection." Wright State University / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=wright1590945950982052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ferreira, Fernando António da Costa. "Distribuição nuclear, dinâmica e função das topoisomerases I, IIα e IIβ na replicação de genomas : estudo experimental no adenovírus serótipo 2-." Doctoral thesis, Universidade Técnica de Lisboa. Faculdade de Medicina Veterinária, 2008. http://hdl.handle.net/10400.5/224.

Full text
Abstract:
Projectos de Investigação no âmbito dos quais o trabalho foi realizado:2001/05 - Cell biology of human topoisomerase IIα (Fundação para a Ciência e a Tecnologia – Programa Operacional Ciência, Tecnologia e Inovação/BCI/36194/2000. 2005/07 - Topoisomerases: at the border between DNA replication and chromatin structure (Fundação para a Ciência e a Tecnologia – Programa Operacional de Ciência e Inovação/BIA-BCM/63368/2004)
Tese de Doutoramento em Ciências Veterinárias
Neste trabalho foi estudado o papel das topoisomerases celulares (I, IIα e IIβ) na replicação, usando os adenovírus como modelo. Os adenovírus apresentam um genoma de ADN de cadeia dupla e são responsáveis por infecções respiratórias, gastro-intestinais, oftalmológicas, neurológicas e genito-urinárias. São organismos ubiquitários, infectam passáros e a maioria dos mamíferos, incluindo o Homem. Com efeito, a importância destes vírus tem vindo a aumentar por surgirem associados a novos quadros nosológicos (imunodeficiências, transplantes de órgãos) e por poderem vir a funcionar como vectores terapêuticos em doenças genéticas e na viroterapia do cancro. No presente trabalho (1) analisámos a distribuição das topoisomerases I, IIα e IIβ no núcleo de células infectadas, com utilização de tecnologias modernas de microscopia, (2) caracterizámos funcionalmente os locais de acumulação destas enzimas, (3) testámos se a replicação e a transcrição virais eram necessárias ao seu recrutamento, (4) estudámos a dinâmica das topoisomerases I e IIα in vivo por FRAP, (5) realizámos a analise mutacional da topoisomerase I e (6) quantificámos as concentrações e actividades catalíticas das topoisomerases antes e depois da infecção. Por fim, (7) abordámos a conexão funcional entre estas proteínas celulares e a replicação do vírus por depleção selectiva de cada topoisomerase (siRNA), evitando os efeitos genotóxicos dos fármacos antitopoisomerase. Os resultados obtidos permitem concluir que ambos os tipos de topoisomerases (I e II) são utilizados pelo adenovírus durante a sua replicação, mas que o seu papel é diferencial, com relevo inesperado para as topoisomerases IIα e IIβ. Estes resultados sugerem que as topoisomerases poderão ser potenciais alvos na terapêutica de patologias infecciosas e potenciais factores preditivos na terapêutica viral do cancro.
APA, Harvard, Vancouver, ISO, and other styles
8

Duarte, Patrícia. "Desenvolvimento da linhagem celular LEY79SF para produção de adenovírus livre de partículas competentes de replicação." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/42/42134/tde-09022010-110303/.

Full text
Abstract:
A presença de Ad com competência para replicar (RCA, replication-competent adenovirus) nas preparações é um dos maiores problemas para a produção de Ad em larga escala. RCAs são gerados pela recombinação entre seqüência do vetor e seqüência homóloga do gene E1 presente nas células helper. Objetivo: desenvolver uma nova linhagem auxiliar para produção de Ad livre de RCA - LEY79 - derivada da linhagem de retinoblastoma humano Y79, tratando-se da primeira linhagem empacotadora de adenovírus com inativação mutacional da proteína supressora de tumor pRb, que crescem em suspensão. Células Y79 foram infectadas com o retrovírus pCLDE1A/E1BSN, selecionadas com G418. A eficiência de produção de AdeGFP na linhagem LEY79 foi testada e comparada com a HEK293A. Células Y79 foram adaptadas em meio livre de soro. Esperamos com a linhagem LEY79SF inovar no campo de processos para a produção de Ad recombinante.
The presence of Ad with the ability to replicate (RCA, replication-competent adenovirus) in preparations is a major problem in the large-scale production of Ad. RCAs are generated by recombination between the vector sequence and sequence of the homologous gene in E1 helper cells. Objective: To develop a new helper cell line for the production of RCA-free Ad., called LEY79, derived from the Y79 of human retinoblastoma line, the first line Packer adenovirus with mutational inactivation of the tumor suppressor protein pRb, which are adapted to grow in suspension. Y79 cells were infected with the retrovirus pCLDE1A/E1BSN, selected with G418. The efficiency of production of AdeGFP in the LEY79 was tested and compared with the HEK293A. Y79 cells were adapted to grow in serum-free medium. We hope that use of the the LEY79SF cell line will promote innovation in the processing and production of recombinant Ad.
APA, Harvard, Vancouver, ISO, and other styles
9

Guissoni, Ana Carla Peixoto. "Análise proteômica de células a-549 infectadas por adenovírus espécie f sorotipo 40 (HAdV-40)." Universidade Federal de Goiás, 2015. http://repositorio.bc.ufg.br/tede/handle/tede/7528.

Full text
Abstract:
Submitted by Cássia Santos (cassia.bcufg@gmail.com) on 2017-07-03T12:16:28Z No. of bitstreams: 2 Tese - Ana Carla Peixoto Guissoni - 2015.pdf: 3062686 bytes, checksum: d470d2e61cd6d74d52b862bd1e76f0c9 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-07-10T11:37:21Z (GMT) No. of bitstreams: 2 Tese - Ana Carla Peixoto Guissoni - 2015.pdf: 3062686 bytes, checksum: d470d2e61cd6d74d52b862bd1e76f0c9 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Made available in DSpace on 2017-07-10T11:37:21Z (GMT). No. of bitstreams: 2 Tese - Ana Carla Peixoto Guissoni - 2015.pdf: 3062686 bytes, checksum: d470d2e61cd6d74d52b862bd1e76f0c9 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2015-08-06
Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq
Human adenovirus (HAdVs) are causative agents of different clinical syndromes such as gastroenteritis, respiratory diseases, eye diseases and cystitis. Adenovirus infection can modify the cellular homeostasis through the interaction with the host cell by inducing proteins of several metabolic pathways. The resulting knowledge of this virus-cell interaction may aid the elucidation of the pathogenic mechanisms caused by adenovirus and the host response against viral infection. To study this interaction, a methodology that has been widely used is proteomics, a tool used in this study, which aimed to identify induced proteins due to viral infection. In this context, we used cells A-549 infected with human adenovirus of type F, serotype 40 (HAdV-40). Infected cells and non-infected cells were used for the osmotic lysis, which were quantified by the Bradford method and then digested with trypsin. Peptides were separated on the LC system in two dimensions. The ionization of the peptides was performed by nano-eletronspray source and through analysis of ToF-MSE system aiming the protein identification. A sum of 336 proteins were identified, 206 of them induced and 130 suppressed by the infection with HAdV-40. The main pathways affected by viral infection were: energy, cellular organization, stress response and apoptosis. It was observed alteration of cell metabolism with increase of the glycolytic pathway, β-oxidation and respiratory chain. Also, the results suggest cytoskeleton reorganization and apoptosis induction. The data can to contribute knowledge about adenovirus pathogenesis considering the proteins related to distinct metabolic pathways induced by viral infection.
Adenovírus humano (HAdVs) são agentes causadores de diversas síndromes clínicas como gastroenterite, doenças respiratórias, oculares e cistite. A infecção por adenovírus pode levar a alterações na homeostase celular a partir da interação com a célula hospedeira pela indução de proteínas de diversas vias metabólicas. O conhecimento resultante desta interação vírus-célula pode auxiliar na elucidação da patogenia destes vírus e na resposta do hospedeiro contra a infecção viral. Para o estudo desta interação, uma metodologia que tem sido bastante utilizada é a proteômica, ferramenta esta usada no presente estudo, que tem como finalidade a identificação de proteínas induzidas a partir da infecção viral. Foram utilizadas células A-549 infectadas por adenovírus humano da espécie F, sorotipo 40 (HAdV-40). Para o procedimento, a partir de células infectadas e controles, procedeu-se à extração de proteínas por lise osmótica, as quais foram quantificadas pelo método de Bradford e a seguir digeridas com tripsina. Os peptídeos foram separados em sistema de cromatografia líquida em duas dimensões. A ionização dos peptídeos foi realizada em fonte nano-eletronspray e a análise destes através do sistema ToF-MSE, possibilitanto a identificação das proteínas. Foram identificadas 336 proteínas, sendo 206 induzidas pela infecção por HAdV-40 e 130 reprimidas. As principais vias afetadas pela infecção viral foram: energia, organização celular, resposta ao estresse e apoptose. Observou-se alteração do metabolismo da célula com o aumento da via glicolítica, β-oxidação e da cadeia respiratória. Além disso, os resultados sugerem reorganização do citoesqueleto e indução de apoptose. Esses dados podem contribuir para o conhecimento da patogenia dos adenovírus considerando as proteínas relacionadas com vias metabólicas distintas induzidas pela infecção viral.
APA, Harvard, Vancouver, ISO, and other styles
10

Arcieri, Luis Ernesto Farinha. "Desenvolvimento e avaliação de ferramentas de imunização baseadas na região globular da fibra adenoviral modificada com o domínio C4 da glicoproteína gp120 do HIV." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/42/42132/tde-25112008-121908/.

Full text
Abstract:
A glicoproteína gp120 do HIV apresenta domínios conservados, dentre os quais está o C4. Este domínio está envolvido no reconhecimento da molécula CD4 na superfície das células alvo, e anticorpos dirigidos contra ele neutralizam o vírus. Em trabalho anterior, este domínio foi introduzido dentro da região globular da proteína fibra do adenovírus. Como a fibra adenoviral é estimulante do sistema imune, decidimos testar a capacidade de indução de anticorpos anti-C4 por essa proteína modificada. Assim, foram construídos vetores plasmídicos e adenovirais portando o gene da região globular da fibra adenoviral contendo o domínio C4, que usados na imunização de camundongos induziram anticorpos capazes de reconhecer a proteína gp120. Também construímos um vetor baculoviral expressando essa proteína híbrida, que purificada por HPLC, foi utilizada para imunizar camundongos que também produziram anticorpos capazes de reconhecer a proteína gp120. Nossos dados sugerem que a região globular da fibra adenoviral é uma boa plataforma para a exposição de epítopos de imunização.
HIV glycoprotein gp120 has conserved domains, one of them being the C4 domain. This region is involved in the recognition of the CD4 marker in target cells and antibodies that recognize this domain can block HIV infection. Previously, the C4 domain was introduced in the adenovirus fiber knob. As the adenovirus fiber stimulates de immune system, we decided to test the production of anti-C4 antibodies by this hybrid protein. We constructed plasmid and adenovirus vectors carrying the fiber knob modified with the C4 domain. Immunization of mice with these vectors showed the production of specific antibodies that recognized de gp120 glycoprotein. Also, we constructed a baculovirus vector expressing the hybrid protein, which was purified by HPLC. Mice immunized with this protein also produced antibodies capable of recognizing gp120. Our data suggest that the fiber knob is a good carrier protein for epitope immunization.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Adenoviru"

1

Chillón, Miguel, and Assumpció Bosch, eds. Adenovirus. Totowa, NJ: Humana Press, 2014. http://dx.doi.org/10.1007/978-1-62703-679-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Doerfler, Walter, ed. Adenovirus DNA. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4613-2293-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

S, Di͡a︡chenko N., Smirnov V. V, Instytut mikrobiolohiï i virusolohiï im. D.K. Zabolotnoho., and Semmelweis Orvostudományi Egyetem. Mikrobiológiai Intézet., eds. Adenovirus, kletka, organizm. Kiev: Nauk. dumka, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wold, William S. M. Adenovirus Methods and Protocols. New Jersey: Humana Press, 1998. http://dx.doi.org/10.1385/0896035514.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wold, William S. M., and Ann E. Tollefson, eds. Adenovirus Methods and Protocols. Totowa, NJ: Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59745-277-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

M, Wold William S., and Tollefson Ann E, eds. Adenovirus methods and protocols. 2nd ed. Totowa, N.J: Humana Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Riley, Steven James. Improving adenovirus vectors for gene therapy. [s.l.]: typescript, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

István, Nász. Az adenovírusok pathológiai jelentősége és molekuláris szerkezete: Akadémiai székfoglaló, 1986. február 20. Budapest: Akadémiai Kiadó, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1933-, Doerfler Walter, and Böhm P, eds. The Molecular repertoire of adenoviruses. Berlin: Springer-Verlag, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

1933-, Doerfler Walter, and Böhm Petra, eds. The molecular repertoire of adenoviruses II: Molecular biology of virus-cell interactions. Berlin: Springer-Verlag, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Adenoviru"

1

Menéndez-Conejero, Rosa, Ana J. Pérez-Berná, Gabriela N. Condezo, Alvaro Ortega-Esteban, Marta del Alamo, Pedro J. de Pablo, and Carmen San Martín. "Biophysical Methods to Monitor Structural Aspects of the Adenovirus Infectious Cycle." In Adenovirus, 1–24. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Di Paolo, Nelson C., and Dmitry M. Shayakhmetov. "The Analysis of Innate Immune Response to Adenovirus Using Antibody Arrays." In Adenovirus, 133–41. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ruzsics, Zsolt, Frederic Lemnitzer, and Christian Thirion. "Engineering Adenovirus Genome by Bacterial Artificial Chromosome (BAC) Technology." In Adenovirus, 143–58. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Miravet, Susana, Maria Ontiveros, Jose Piedra, Cristina Penalva, Mercè Monfar, and Miguel Chillón. "Construction, Production, and Purification of Recombinant Adenovirus Vectors." In Adenovirus, 159–73. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Silva, Ana Carina, Paulo Fernandes, Marcos F. Q. Sousa, and Paula M. Alves. "Scalable Production of Adenovirus Vectors." In Adenovirus, 175–96. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Puig, Meritxell, Jose Piedra, Susana Miravet, and María Mercedes Segura. "Canine Adenovirus Downstream Processing Protocol." In Adenovirus, 197–210. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kreppel, Florian. "Production of High-Capacity Adenovirus Vectors." In Adenovirus, 211–29. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Miralles, Marta, Marc Garcia, Marcos Tejero, Assumpció Bosch, and Miguel Chillón. "Production of Chimeric Adenovirus." In Adenovirus, 231–43. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lind, Sara Bergström, Konstantin A. Artemenko, and Ulf Pettersson. "Proteome Analysis of Adenovirus Using Mass Spectrometry." In Adenovirus, 25–44. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Parker, Alan L., Angela C. Bradshaw, Raul Alba, Stuart A. Nicklin, and Andrew H. Baker. "Capsid Modification Strategies for Detargeting Adenoviral Vectors." In Adenovirus, 45–59. Totowa, NJ: Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-679-5_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Adenoviru"

1

Lima, Maríllia Raphaella Cabral Fonseca de, Guilherme Antonio de Souza Silva, Leonardo Carvalho de Oliveira Cruz, Georon Ferreira de Sousa, Bárbara Rafaela da Silva Barros, Rodrigo Cesar Abreu de Aquino, and Cristiane Moutinho Lagos de Melo. "PERFIL DA RESPOSTA IMUNOLÓGICA, EFICÁCIA E EFEITOS COLATERAIS DAS VACINAS EM USO CONTRA A COVID-19 NO BRASIL." In XXVII Semana de Biomedicina Inovação e Ciência. Editora IME, 2021. http://dx.doi.org/10.51161/9786588884119/24.

Full text
Abstract:
Introdução: Com a pandemia da COVID-19, doença causada pelo vírus SARS-CoV- 2¹, o desenvolvimento de uma vacina eficaz ocorreu em tempo recorde, exibindo bons resultados. As vacinas foram criadas com métodos variados, como: vetor viral recombinante, subunidade de proteína, vírus inativados e ácidos nucleicos. No Brasil, a vacinação foi iniciada em 17 de janeiro de 2021, com uso emergencial da CoronaVac e da AstraZeneca. Objetivos: Descrever o perfil da resposta imunológica, eficácia e efeitos colaterais das vacinas contra COVID-19 utilizadas no Brasil. Métodos: Foram selecionados artigos disponíveis na plataforma PubMed. Os critérios de inclusão foram artigos no idioma inglês, publicados nos anos de 2020-2021 com os seguintes descritores: Vacinação; COVID-19; Eficácia; Efeitos Colaterais; e Resposta Imunológica. Resultados/Discussão: A vacina de RNAm da Pfizer induziu elevados títulos de anticorpos neutralizantes para SARS-CoV-2 e resposta T CD4+/CD8+, com eficácia de 95% após a segunda dose, e os efeitos colaterais mais comuns foram fadiga e cefaléia². A AstraZeneca, vacina de adenovírus modificado, apresentou resposta imunológica humoral e celular, além de eficácia de 90% após a segunda dose, possuindo como efeitos adversos mais comuns mialgia, fadiga, cefaléia, dor no local da injeção e febre.³ A Janssen, vacina adenoviral (Ad26) de dose única, demonstrou produção de anticorpos neutralizantes, e resposta celular T CD4+/CD8+, apresentando eficácia variando de 67% a 85% de acordo com a gravidade do caso. Seus os principais efeitos adversos foram dor no local da injeção, cefaléia e fadiga.4 A Sputnik V, vacina adenoviral de imunização heteróloga (Ad26 primeira dose e Ad5 segunda dose), apresentou forte resposta humoral e de células T CD4+/CD8+, e eficácia de 91,4% após a segunda dose, sendo as principais reações adversas astenia, mialgia, artralgia, febre e cefaléia. A CoronaVac, vacina de vírus inteiro inativado, induziu a produção de anticorpos contra o SARS-CoV-2, além de uma resposta celular de linfócitos T produtores de IFN-γ, apresentou eficácia que variou entre 83,7% e 100% após a segunda dose, dependendo da gravidade, e a principal reação adversa foi a dor no local da aplicação.5 Conclusões: O perfil de resposta imunológica é, principalmente, produção de anticorpos neutralizantes e resposta T CD4+/CD8+. As eficácias das vacinas em uso no Brasil variam entre 66% - 91,4% após a imunização completa e o principal efeito colateral foi a cefaléia.
APA, Harvard, Vancouver, ISO, and other styles
2

Blay, C., C. Butler, and A. Ataya. "ARDS Secondary to Adenovirus." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1795.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mirabal Moray, Matilde, Manuel Colomé Hidalgo, Olga Jape Collins, Jaime Soto Urdaneta, and Ramos Sánchez Erick. "RELACIÓN ENTRE LA HEPATITIS AGUDA GRAVE DE ETIOLOGÍA DESCONOCIDA EN NIÑOS Y LOS ADENOVIRUS." In VII CONGRESO INVESTIGACIÓN, DESARROLLO E INNOVACIÓN DE LA UNIVERSIDAD INTERNACIONAL DE CIENCIA Y TECNOLOGÍA. Universidad Internacional de Ciencia y Tecnología, 2022. http://dx.doi.org/10.47300/actasidi-unicyt-2022-31.

Full text
Abstract:
En abril de 2022, el Reino Unido notificó por primera vez un aumento significativo e inesperado de casos de hepatitis aguda grave de etiología desconocida en niños previamente sanos. Desde entonces y hasta julio del 2022, se han notificado a la OMS al menos 1010 casos probables de hepatitis aguda de etiología desconocida en 35 países. El rango de edad de los afectados abarca entre 30 días y 16 años de vida. Los signos y síntomas más comunes son náuseas, vómitos, ictericia, malestar general y dolor abdominal. De los casos notificados, al menos 46 han requerido trasplante y se han reportado 22 defunciones. La Región Europea de la OMS actualmente notifica la mayoría de los casos y en segundo lugar la región de las Américas. Se espera que los números de casos fluctúen a medida que la comunidad mundial comprenda más acerca de las posibles causas y que se realicen investigaciones activas y retrospectivas en diferentes países. La infección por adenovirus detectada en los casos de hepatitis a través de reacción de cadena de polimerasa abre líneas de investigación para profundizar sobre el tema. En los diferentes países donde ha aparecido casos de hepatitis aguda grave de origen desconocido existe circulación de adenovirus, demostrando su posible papel como agente etiológico. Determinar la etiología de estos casos permite mejorar el entendimiento de la enfermedad para perfeccionar las acciones de control y prevención.
APA, Harvard, Vancouver, ISO, and other styles
4

Flores, Carlos E., Mireya Méndez, Bernardita Chateau, Claudia Astudillo, Hugo Cerda, Soledad Montes, and Tatiana Espinoza. "Attack Rate Of Adenovirus In Childrens Hospital." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a4933.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Miura, Yoshiaki, Julia Davydova, and Masato Yamamoto. "Abstract 5655: Infectivity selective oncolytic adenovirus for pancreatic cancer by redesigning the AB-loop via adenovirus library screening." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5655.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Liu, Kai, Xiuhong Liu, Tao Wen, Feng Ren, Jiming Yin, Daojie Liu, Huiguo Ding, Ning Li, and Dexi Chen. "Abstract 789: Adenovirus p53 enhances the antitumor effect of adenovirus thymidine kinase/ganciclovir on Hep3B cells by apoptosis." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-789.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Oh, JY, MY Park, SH Shim, MW Sung, and CT Lee. "Combination Gene Therapy with Conditionally Replicating Adenovirus (CRAD) and Adenovirus-Herpes Simplex Virus Thymidine Kinase (ad-HSTK) of Lung Cancer." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Smatti, Maria K., Hamad E. Al-Romaihi, Hebah A. Al-Khatib, Peter V. Coyle, Asmaa A. Al Thani, Muna A. Al Maslamani, and Hadi M. Yassine. "Influenza, RSV, and Other Respiratory Infections among Children in Qatar." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0133.

Full text
Abstract:
Background: Acute respiratory infections (ARIs) lead to high rates of mortality and morbidity among children. However, studies on the etiology of respiratory infections among children in Qatar and surrounding countries are still limited. Objectives: To describe the prevalence and seasonality of RSV, influenza, and other respiratory pathogens among children in Qatar. Methods: We retrospectively collected data of 33,404 patients <15 years old presented with Influenza-like illness (ILI) from 2012 to 2017. All samples were tested for influenza viruses, while 30,946 were tested for a complete panel of 21 respiratory pathogens. Results: At least one respiratory pathogen was detected in 26,138 (78%) of patients. Together, human rhinoviruses (HRV), respiratory syncytial virus (RSV), and influenza viruses comprised nearly two-thirds of all ILI cases, detected in 24%, 19.7%, and 18.5%, respectively. A detection rate of 5-10% was recorded for adenovirus, human parainfluenza viruses (HPIVs), bocavirus (HboV), and human coronaviruses (HCoVs). Other pathogens such as human metapneumovirus (HMPV), enteroviruses, mycoplasma pneumonia, and parechovirus had prevalence rates below 5%. ILI positive cases were detected throughout the year. RSV, influenza, HMPV exhibited strong seasonal activity in the winter, while HRV was primarily active during low RSV and influenza activity. The burden of RSV exceeds that of influenza among young age groups (<5 years), affecting 17-30% of ILI cases. Prevalence of influenza, on the other hand, correlated positively with age, ranging from 23% to 32% in age groups above five years. Further, male patients had higher rates of HRV (26%) and adenovirus (9%), whereas females showed a higher prevalence of influenza (22%), and RSV (20%) infections. Conclusion: This comprehensive report provides insights into the etiology of ILI among children in Qatar, which represents the Gulf region. Our results reinforce the significance of active surveillance of respiratory pathogens to improve infection prevention and control strategies, particularly among children.
APA, Harvard, Vancouver, ISO, and other styles
9

Xiong, Z., and X. Lu. "Inactivate adenovirus by using a room temperature plasma needle." In 2012 IEEE 39th International Conference on Plasma Sciences (ICOPS). IEEE, 2012. http://dx.doi.org/10.1109/plasma.2012.6383550.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Li, De-Chun, Shi-Ying Zheng, Jun Zhao, and Jin-Feng Ge. "Adenovirus-Mediated FasL gEne Transfer Into Human Gastric Carcinoma." In 2008 2nd International Conference on Bioinformatics and Biomedical Engineering. IEEE, 2008. http://dx.doi.org/10.1109/icbbe.2008.104.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Adenoviru"

1

Pai, Menaka, Benjamin Chan, Nathan M. Stall, Allan Grill, Noah Ivers, Antonina Maltsev, Katherine J. Miller, et al. Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination: Lay Summary. Ontario COVID-19 Science Advisory Table, May 2021. http://dx.doi.org/10.47326/ocsat.2021.02.16.2.0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Curiel, David T. Conditionally Replicative Adenovirus for Prostate Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, April 2001. http://dx.doi.org/10.21236/ada395216.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Malasig, Marietta D., Pulak R. Goswami, Leta K. Crawford-Mkisza, David P. Schnurr, and Gregory C. Gray. Simplified Microneutralization Test for Serotyping Adenovirus Isolates. Fort Belvoir, VA: Defense Technical Information Center, August 2001. http://dx.doi.org/10.21236/ada408858.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Balliram, Niranjan. Adenovirus Vaccine Shortfall: Impact on Readiness and Deployability. Fort Belvoir, VA: Defense Technical Information Center, December 2001. http://dx.doi.org/10.21236/ada403017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kaliberov, Sergey A. Therapy of Breast Cancers Using Conditionally Replicating Adenovirus. Fort Belvoir, VA: Defense Technical Information Center, August 2005. http://dx.doi.org/10.21236/ada447528.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dewhurst, Stephen. New Conditionally Replicating Adenovirus Vectors for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2008. http://dx.doi.org/10.21236/ada502798.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dmitriev, Igor P. An Oncotropic Adenovirus Vector System for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, September 2005. http://dx.doi.org/10.21236/ada446322.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dmitriev, Igor P. An Oncotropic Adenovirus Vector System for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, September 2004. http://dx.doi.org/10.21236/ada430028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ding, Vivanne. Midkine Promoter-Driven Adenovirus as Potential Therapy for NF1. Fort Belvoir, VA: Defense Technical Information Center, December 2006. http://dx.doi.org/10.21236/ada467964.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ding, Yi. Adenovirus-Mediated p202 Gene Transfer in Breast Cancer Gene Therapy. Fort Belvoir, VA: Defense Technical Information Center, May 2005. http://dx.doi.org/10.21236/ada442740.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Adenoviru' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography